Versuchen GOLD - Frei

analytica Lab India focuses on innovative solutions

Chronicle Pharmabiz

|

September 18, 2025

EVEN as the laboratory world is developing rapidly, analytica Lab India, the largest and most important platform for the analysis, laboratory-technology and biotechnology market in India, stands as a testimony to the growing prowess of these sectors.

Scheduled to take place from September 18 to 20, 2025 at HITEX Exhibition Centre, Hyderabad, analytica Lab India focuses on innovative and applied product and system solutions for laboratories in the industrial, research and science sectors. As the industry's definitive forum, fair and conference gather all relevant information about the latest developments.

As the industry’s most important marketplace, analytica Lab India brings together scientists, entrepreneurs and users from all over the world. India being one of the most promising markets of the future, participants would benefit from excellent business opportunities.

analytica Lab India, South Asia’s leading marketplace for laboratory technologies and analytical instruments, brings together international and domestic manufacturers, laboratory users, consultants, and key government officials on one platform, creating an ideal environment for networking and fostering business collaborations among industry professionals.

analytica Lab India is part of the global exhibition network, which includes analytica in Munich, analytica China, analytica Vietnam, and analytica Lab Africa.

This event happens twice in Mumbai & Hyderabad respectively. The Mumbai edition hosted over 165 exhibitors displaying 3000 products and solutions and attracted audience of over 6024 visitors across 3 days in 2024 edition.

The Hyderabad edition happened in co-location with Pharma Pro&Pack Epxo. These events together hosted over 528 exhibitors and attracted audience of over 24,533 visitors across 8 halls in the 2024 edition.

WEITERE GESCHICHTEN VON Chronicle Pharmabiz

Chronicle Pharmabiz

Biocon gets US FDA nod for Bosaya & Aukelso

BIOCON Biologics, a fully integrated global biosimilars company and subsidiary of Biocon has received the US Food and Drug Administration (FDA) approval for Bosaya (denosumab-kyqq) 60 mg/mL injection for subcutaneous use in a single dose prefilled syringe (PFS), and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial, biosimilars of Prolia and Xgeva respectively.

time to read

1 mins

September 25, 2025

Chronicle Pharmabiz

Centre to appoint 49 drug inspectors in CDSCO

THE Union Ministry of Health and Family Welfare has notified recruitment of 49 drug inspectors under the Central Drugs Standard Control Organisation (CDSCO), as part of strengthening the organisation's operations to regulate and monitor the drugs and pharmaceutical industry and market in the country.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

Cold Chain Community to hold conference in Ahmedabad

IN order to create new opportunities in the pharmaceutical cold chain sector, Cold Chain Community, a knowledge-based business platform powered by the National Accreditation Body for Cold Chain Management (NAB-CCM), will hold one-day conference on November 4, 2025 in Ahmedabad.

time to read

1 mins

September 25, 2025

Chronicle Pharmabiz

HC appoints team to conduct inspection on Palamur Bio's facility

THE Delhi High Court (HC) has appointed a three-member inspection team to conduct fresh inspection at the facility of Telan-gana-based preclinical contract research organisation Palamur Biosciences in connection with the allegations raised by the People for the Ethical Treatment of Animals India (PETA India) pertaining to abuse and neglect of animals while carrying out experimentation.

time to read

2 mins

September 25, 2025

Chronicle Pharmabiz

Merck gets 2 positive opinions from CHMP for Keytruda

MERCK, known as MSD outside of the US and Canada, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for Keytruda (pembrolizumab), which if approved would be marketed in the European Union (EU) as Keytruda SC.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

Aptar's Enbumyst receives US FDA nod

APTAR Pharma, a global leader in drug delivery and active material science solutions and services, announced that its unidose liquid system is the delivery system for the recent US FDA-approved Enbumyst (Bumetanide nasal spray) 0.5mg by Corstasis Therapeutics.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

Health insurance faces headwinds of escalating medical inflation

HEALTH insurance industry is entering a period of financial stress, driven by two critical factors.

time to read

2 mins

September 25, 2025

Chronicle Pharmabiz

NABL, Ladakh Univ team up to enhance lab capabilities

THE National Accreditation Board for Testing and Calibration Laboratories (NABL) and the University of Ladakh have partnered to enhance testing laboratory capabilities, research, and skill development in Ladakh.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

AICDF blows whistle on drug cos in U'khand

IN a bold move that could shake the pharmaceutical sector, the All India Chemists and Distributors Federation (AICDF) has submitted a scathing complaint to the National Pharmaceutical Pricing Authority (NPPA), raising serious concerns over the activities of certain drug manufacturers operating out of Uttarakhand.

time to read

2 mins

September 25, 2025

Chronicle Pharmabiz

HC appoints team to conduct inspection on Palamur Bio's facility

THE Delhi High Court (HC) has appointed a three-member inspection team to conduct fresh inspection at the facility of Telangana-based preclinical contract research organisation Palamur Biosciences in connection with the allegations raised by the People for the Ethical Treatment of Animals India (PETA India) pertaining to abuse and neglect of animals while carrying out experimentation.

time to read

2 mins

September 25, 2025

Listen

Translate

Share

-
+

Change font size